相似文献
1
IL15 and IL21: Better When Membrane-Tethered Together on Antitumor T Cells.
Clin Cancer Res. 2024 Apr 15;30(8):1431-1433. doi: 10.1158/1078-0432.CCR-23-3466.
2
Cooperative Armoring of CAR and TCR T Cells by T Cell-Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy.
Clin Cancer Res. 2024 Apr 15;30(8):1555-1566. doi: 10.1158/1078-0432.CCR-23-1872.
3
Identification of a γc Receptor Antagonist That Prevents Reprogramming of Human Tissue-resident Cytotoxic T Cells by IL15 and IL21.
Gastroenterology. 2020 Feb;158(3):625-637.e13. doi: 10.1053/j.gastro.2019.10.006. Epub 2019 Oct 14.
4
Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
Cancer Immunol Res. 2020 Mar;8(3):309-320. doi: 10.1158/2326-6066.CIR-19-0293. Epub 2020 Jan 17.
5
IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype.
Cancer Immunol Res. 2019 May;7(5):759-772. doi: 10.1158/2326-6066.CIR-18-0466. Epub 2019 Mar 19.
6
Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Antitumor Cytotoxicity against Neuroblastoma.
Clin Cancer Res. 2022 Sep 1;28(17):3785-3796. doi: 10.1158/1078-0432.CCR-22-0717.
7
Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model.
J Immunother Cancer. 2024 Jul 1;12(7):e008572. doi: 10.1136/jitc-2023-008572.
8
Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer.
Gene Ther. 2010 Jun;17(6):721-32. doi: 10.1038/gt.2010.4. Epub 2010 Feb 18.
9
Targeted therapy of multiple myeloma by IL21-NKG2D CAR-T cells.
J Investig Med. 2025 Jan;73(1):45-53. doi: 10.1177/10815589241291846. Epub 2024 Nov 1.
10
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy.
Cancer Res. 2015 Dec 15;75(24):5187-5193. doi: 10.1158/0008-5472.CAN-15-1498. Epub 2015 Dec 1.
引用本文的文献
1
Onboard, tethered IL-12 boosts potency of the Tmod NOT gate and preserves selectivity.
J Immunother Cancer. 2025 May 21;13(5):e010976. doi: 10.1136/jitc-2024-010976.
2
Anti-CD137 agonist antibody-independent and clinically feasible preparation of tumor-infiltrating lymphocytes from soft tissue sarcoma and osteosarcoma.
Front Immunol. 2025 Mar 12;16:1557006. doi: 10.3389/fimmu.2025.1557006. eCollection 2025.
本文引用的文献
1
Cooperative Armoring of CAR and TCR T Cells by T Cell-Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy.
Clin Cancer Res. 2024 Apr 15;30(8):1555-1566. doi: 10.1158/1078-0432.CCR-23-1872.
2
PD-1 combination therapy with IL-2 modifies CD8 T cell exhaustion program.
Nature. 2022 Oct;610(7930):173-181. doi: 10.1038/s41586-022-05257-0. Epub 2022 Sep 28.
3
Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers.
J Immunol. 2022 Mar 15;208(6):1362-1370. doi: 10.4049/jimmunol.2100066. Epub 2022 Feb 28.
4
An NK-like CAR T cell transition in CAR T cell dysfunction.
Cell. 2021 Dec 9;184(25):6081-6100.e26. doi: 10.1016/j.cell.2021.11.016. Epub 2021 Dec 2.
5
IL-15 in the Combination Immunotherapy of Cancer.
Front Immunol. 2020 May 19;11:868. doi: 10.3389/fimmu.2020.00868. eCollection 2020.
6
Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines.
Front Immunol. 2019 Feb 20;10:263. doi: 10.3389/fimmu.2019.00263. eCollection 2019.
7
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Lancet Oncol. 2018 May;19(5):694-704. doi: 10.1016/S1470-2045(18)30148-7. Epub 2018 Apr 5.
8
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy.
Cancer Res. 2015 Dec 15;75(24):5187-5193. doi: 10.1158/0008-5472.CAN-15-1498. Epub 2015 Dec 1.
9
IL-21: a pleiotropic cytokine with potential applications in oncology.
J Immunol Res. 2015;2015:696578. doi: 10.1155/2015/696578. Epub 2015 Apr 15.
10
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
J Clin Oncol. 2015 Jan 1;33(1):74-82. doi: 10.1200/JCO.2014.57.3329. Epub 2014 Nov 17.
Zotero 插件